MADRID, Feb 16 (Reuters) - The Spanish region of Valencia has resumed cervical cancer vaccinations using Merck & Co’s (MRK.N) Gardasil, a spokeswoman for Valencia’s health authority said on Monday.
Use of the vaccine was halted last Monday when two girls fell ill after receiving injections from the same batch of the drug.
“The batch which the sick girls recieved is still suspended and being investigated, but injections from other batches of Gardasil resumed today,” the spokeswoman said.
Merck markets the vaccine, which is meant to protect against cancer-causing strains of the sexually transmitted human papillomavirus (HPV), in Europe with Sanofi-Aventis SA (SASY.PA).
It competes with GlaxoSmithKline Plc’s (GSK.L) Cervarix. [nLA563086] (Reporting by Jonathan Gleave; Editing by David Holmes)